A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa

NCT06891885 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Retinitis Pigmentosa

Interventions

DRUG: DSP-3077 Retinal Sheet Cohort 1
DRUG: DSP-3077 Retinal Sheet Cohort 2
DRUG: DSP-3077 Retinal Sheet Cohort 3

Sponsor

Sumitomo Pharma America, Inc.